Karyopharm Therapeutics Inc. filed a current report on November 2, 2026, disclosing that it has entered into a Restructuring Support Agreement and filed voluntary Chapter 11 bankruptcy petitions in connection with a planned merger with Ayrmid Ltd.

Key Highlights

  • Chapter 11 filing: Karyopharm filed voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas.
  • Restructuring Support Agreement: The company entered into a Restructuring Support Agreement with its existing lenders, noteholders, and other key stakeholders.
  • Merger with Ayrmid: The agreement provides for a merger between Ayrmid Ltd. and a reorganized Karyopharm, to be implemented through a Chapter 11 plan.
  • Expected close: The transaction is expected to close in the first quarter of 2027, subject to conditions described in the Chapter 11 plan.
  • Competing bids: The company will seek court approval of bidding procedures to allow other parties to submit competing proposals and bids for the company's assets.
  • Equity value warning: According to the filing, the Prepackaged Plan provides that holders of common stock and Convertible Preferred Stock "will not receive any payment or other distribution on account of such securities," and the company "expects that its existing equity securities will have no value."

Karyopharm Discloses Chapter 11 Proceedings and Merger Agreement With Ayrmid Ltd.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a Delaware-incorporated biopharmaceutical company headquartered in Newton, Massachusetts, disclosed on November 2, 2026, that it has filed voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code. The filing was made in the United States Bankruptcy Court for the Southern District of Texas, according to the Form 8-K submitted under Item 7.01 Regulation FD Disclosure.

The company reported that it has entered into a Restructuring Support Agreement with its existing lenders, noteholders, and other key stakeholders. That agreement provides for a merger between Ayrmid Ltd. and a reorganized Karyopharm, referred to in the filing as "the Transaction." The company disclosed that it intends to implement the Transaction through a Chapter 11 plan and will seek court approval of bidding procedures. Those procedures, the filing states, "will allow other parties to submit competing proposals and bids for the Company's assets." The Transaction is expected to close in the first quarter of 2027, subject to the conditions described in the Chapter 11 plan.

The filing includes an explicit cautionary statement directed at securityholders. According to the company's disclosure, "trading in the Company's securities during the pendency of the Cases is highly speculative and poses substantial risks," and "trading prices for the Company's securities may bear little or no relationship to the actual recovery, if any, by the Company's securityholders in the Cases." The company further stated that it "expects that its existing equity securities will have no value and that holders of such securities will experience a complete loss on their investment." The filing was signed by Michael Mano, Executive Vice President, Chief Legal Officer and Secretary.

What Was Disclosed

Karyopharm Therapeutics filed a Form 8-K on November 2, 2026, reporting its voluntary Chapter 11 filing, a Restructuring Support Agreement with key stakeholders, and a planned merger with Ayrmid Ltd., with the transaction targeted to close in the first quarter of 2027.